Stripe and OpenAI Are Funding a War on the Common Cold

A group of software engineers and AI labs are funding a $500 million nonprofit to prevent respiratory infections. This isn't a moonshot from big pharma; it's a bet from Silicon Valley.

The common cold is a fact of life. So is the flu. For decades, the best advice has been vitamin C and wishful thinking. Now, a payments company thinks it can engineer them out of existence. Stripe, Anthropic, and the OpenAI Foundation have put their weight behind a new $500 million nonprofit called Intercept, which aims to prevent respiratory infections altogether. This isn't a moonshot from Pfizer or GSK. It’s a group of software engineers, AI researchers, and venture capitalists deciding that a biological problem is really just a market-failure problem with a technical solution.

You can’t make one vaccine for the sniffles because the condition is caused by more than 200 different viruses, according to the American Lung Association. Intercept’s strategy, therefore, isn’t to chase any single pathogen. It’s a portfolio of bets on broad-spectrum countermeasures. One idea involves engineering virus-trapping proteins that you could spray into your nose, acting like a biological filter. Another focuses on RNA drugs and monoclonal antibodies designed to work against entire families of viruses, not just specific strains. They're also backing brute-force environmental engineering: large-scale air purification systems using far-UVC light to scrub viruses from schools and offices, treating breathable air like a public utility.

The money explains the mission. Big pharma shies away from a cold vaccine because the R&D is a nightmare for a low-margin payoff. As MIT Technology Review reports, Stripe's leadership sees this as a classic incentive problem, not a scientific dead end. So tech philanthropy is stepping in. The initial fund comes from Stripe, AI labs Anthropic and OpenAI, Bill Gates, and traders from Jane Street Capital. They’ve recruited heavyweights like Moncef Slaoui, who ran the US COVID vaccine effort, as an advisor. Stripe did this before with its Frontier fund for carbon removal; now it's aiming the same model at rhinoviruses.

The COVID-19 pandemic provided the proof of concept: immense capital plus new biotech tools can collapse drug development timelines from a decade to a year. Intercept is a bet that this model can be applied systemically, not just in a crisis. The goal is to move from reacting to outbreaks to proactively engineering a world where they don't happen. Within five years, we will see whether these bets yield a nasal spray that actually works or just more advanced UV lighting in new office buildings. The bigger question isn't whether the tech will function. It's who gets to set the priorities for human health—biologists and doctors, or the people who build payment processors and large language models?